An interventional study of EXPO and EXPO Extended in Down Syndrome and Trisomy 21, sponsored by Colorado State University. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 36 Months to 72 Months. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Colorado State University · Not applicable, Interventional, and Treatment
The Executive Function Play Opportunities (EXPO) study is a sequential, multiple assignment, randomized trial (SMART) evaluating adaptive caregiver-mediated intervention pathways for improving executive function (EF) in children with Down syndrome (DS). At baseline, participants will be randomized in a 1:4 ratio to receive either a delayed-treatment control condition or the EXPO intervention. After 4 weeks of standard EXPO intervention in stage 1, participants in the EXPO condition will be assessed for response to the intervention based on prespecified criteria for improvement in laboratory-based EF performance. Early responders will continue with the standard EXPO intervention in stage 2. Slower responders will be randomized to either the EXPO Extended or EXPO Foundations pathway. All participants will complete laboratory and parent-report measures of EF immediately post-intervention and 3 months later. Participants in the delayed-treatment control condition will complete the same assessments as the EXPO groups and will be offered the EXPO intervention after completion of the 3-month follow-up.
The Executive Function Play Opportunities (EXPO) study is a sequential, multiple assignment, randomized trial (SMART) evaluating adaptive caregiver-mediated intervention pathways for improving executive function (EF) in children with Down syndrome (DS). At baseline, all participants will complete an assessment including laboratory-based measures of EF, parent-report measures of EF, and intensive ecological measurement of EF using the iBehavior app. Participants will then be randomized in a 1:4 ratio to receive either a delayed-treatment control condition or the EXPO intervention, with a target total sample size of 150.
During stage 1, participants in the EXPO condition will complete 4 weeks of standard EXPO intervention. The initial weeks of EXPO consist of 2 weeks of EXPO Ready activities followed by 2 weeks of Working Memory activities, and all participants in the EXPO intervention receive ongoing support from an EXPO coach.
At the stage 1 evaluation, conducted 4 weeks after starting EXPO, all participants will complete the laboratory-based EF assessment battery. EXPO participants will be assessed for response to the intervention and classified as early or slower responders based on prespecified criteria for improvement in laboratory-based EF performance.
Early responders will be assigned to the standard EXPO intervention in stage 2 and continue with activities targeting inhibition, cognitive flexibility, planning, and consolidation of skills for a total of 12 weeks. Slower responders will be randomly assigned in a 1:1 ratio to either the EXPO Extended or EXPO Foundations pathway. The EXPO Extended pathway will include the same core activities as the EXPO standard pathway but will provide additional intervention time, for a total of 18 weeks. The EXPO Foundations pathway will begin with a block of activities targeting early social communication and regulation to provide a foundation for activity engagement, followed by more foundational versions of activities targeting inhibition and cognitive flexibility. The EXPO Foundations pathway will continue for a total of 12 weeks.
All participants will complete laboratory and parent-report measures of EF immediately post-intervention and 3 months later. Participants in the delayed-treatment control condition will not receive EXPO during the initial study period but will complete the same assessments as participants in the EXPO intervention. Following completion of the 3-month follow-up, participants in the delayed-treatment control condition will be offered the EXPO intervention.
438 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.
This study's planned enrollment of 150 is above the median of 37 across 286 interventional studies indexed under Down Syndrome.
Browse Down Syndrome studies →Colorado State University is the lead sponsor of 117 studies on the registry; 19 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants do not receive EXPO during the initial study period and complete the same EF assessments as participants in the EXPO intervention pathways. Participants are offered the EXPO intervention following completion of the 3-month follow-up.
Early responders to EXPO at the stage 1 evaluation are assigned to the standard, 12 -week intervention with activities refined from EXPO 2.0.
Behavioral: EXPO
Half of participants classified as slower responders to EXPO at the stage 1 evaluation are randomly assigned to EXPO Extended. EXPO Extended provides the standard pathway activities with an extended 18-week schedule.
Behavioral: EXPO Extended
Half of participants classified as slower responders to EXPO at the stage 1 evaluation are randomly assigned to EXPO Foundations. EXPO Foundations provides a more foundational pathway with simplified activities, and additional activities that emphasize early communication and regulatory processes.
Behavioral: EXPO Foundations
EXPO is a novel intervention that targets the development of EF through play-based opportunities for children with DS and their primary caregivers. EXPO is a 'syndrome-informed' intervention in that all activities are tailored to phenotypic strengths and challenges associated with DS, accounting for cognitive, language, and motor presentations frequently observed in this population. EXPO is also designed to elicit maximal engagement and enjoyment for children and their caregivers by embedding opportunities to strengthen EF component processes in the context of play and games.
Also known as: Executive Function Play Opportunities
Alternative EXPO pathway that extends the length of the EXPO intervention from 12 to 18 weeks to provide more time and opportunity for skill acquisition.
An augmented version of EXPO that places a greater emphasis on precursors to EXPO activity engagement, including an increased number of social routine activities, enhanced presses for social communication behaviors like joint attention, enhanced focus on early self-regulation skills, and adaptations of all EXPO activities in each block that emphasize more foundational aspects of play.
Adapted Reverse Categorization
Rule switch task that involves sorting by color, and then reversing the sort rule. Scores are calculated as the number of items correctly sorted after reversing the sort rule; scores range from 0 to 10 and a higher score indicates a better outcome.
Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
Zoo Animal Switch
Rule switch task that involves sorting large and small animal pairs by size into large and small buckets, then reversing the rule to put large animals into the small bucket, and small animals into the large bucket. Scores are calculated as the number of items correctly sorted after reversing the sort rule; scores range from 0 to 10 and a higher score indicates a better outcome.
Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
Developmental Profiles-4 Cognitive domain
Growth Scale Values in the Developmental Profiles-4 Cognitive domain. Growth scale values (GSV) are vertically scaled scores designed to track real skill gains over time; scores range from approximately 300 to 800 and a higher score indicates a better outcome.
Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
Developmental Profiles-4 Social-emotional domain
Growth Scale Values in the Developemental Profiles-4 Social-Emotional domain. Growth scale values (GSV) are vertically scaled scores designed to track real skill gains over time; scores range from approximately 400 to 600 and a higher score indicates a better outcome.
Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
iBehavior Ecological Momentary Assessment
This daily report will be completed in week-long bursts by families. Families respond to a 29-item questionnaire that asks about daily use of executive function skills. A lower score indicates a better outcome.
Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
Self ordered pointing: Garage Game
Self-ordered pointing task that requires working memory/updating
Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
BRIEF-Preschool Inhibition Domain
Standardized Caregiver Report of Executive Functioning for Preschool aged children
Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
Hearts and Flowers
Opposites task that involves matching cards to the opposite type of card
Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
Developmental Profiles-4 Adaptive Behavior domain
Growth Scale Values in the Developmental Profiles-4 Adaptive Behavior domain
Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
Building Task
Shape design task that involves reproducing a pattern of blocks according to a design produced by the examiner
Time frame: From enrollment to 12 or 18 weeks (depending on condition) with a 3-month follow-up
Plan to share: Yes — Upon completion of this study, and annually throughout the three-year project period, our team will share all developmental and behavioral data with the NIH INCLUDE Data Coordinating Center (DCC). Data will also be collected from a parent or guardian via questionnaire and the iBehavior smartphone application. Data that will be preserved and shared include demographic information, developmental assessments composite scores, caregiver rating composite scores for behavioral dimensions, and caregiver-reported iBehavior composite data. The data transformation approach for all aggregate-level data will be specified in detail in a protocol manual for reproducibility. Information regarding data content, format, and organization will be available to any research colleagues accessing the DCC database. All shared data will be formatted in accordance with current standards and norms in the field.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Nov 30, 2029
Access criteria: Data will be made available within the National Institutes of Health (NIH) INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Data Coordinating Center (DCC) system, allowing researchers to access it in accordance with their approved access level. All data and secondary analyses will be included in the DCC. The DCC will use its current policies and procedures for access by interested research teams.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.
Of 163 non-industry interventional studies with no phase under Down Syndrome, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 35. This study's planned 36 months is above that.
Counting every sponsor, half of 165 studies reached it within 11 months; a quarter within 3 and three quarters within 35.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Sep 2026 → Dec 2026, primary completion Aug 2029 → Dec 2029 and completion Nov 2029 → Jan 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.